1 / 17

Antibiotic resistance a new pandemia

Antibiotic resistance a new pandemia. Economic and social impact of antibiotic resistance. ca. 25 000 patients per year die from antibiotic resistant infections ca. 2.5 Mio. extra hospital days to a cost of EUR 900 Mio. Out-patient care costs increase ca. EUR 10 Mio.

oliver
Download Presentation

Antibiotic resistance a new pandemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antibiotic resistancea new pandemia

  2. Economic and social impact ofantibiotic resistance • ca. 25 000 patients per year die from antibiotic resistant infections • ca. 2.5 Mio. extra hospital days to a cost of EUR 900 Mio. • Out-patient care costs increase ca. EUR 10 Mio. • Loss of work costs EUR 150 Mio. • Productivity losses are estimated to around EUR 150 Mio.  Overall social costs of antibiotic-resistant infections are estimated to EUR 1.5 billion each year.

  3. Recent initiatives • European Antibiotic Awareness Day • EU/US transatlantic task force on antibiotic resistance • A conference on incentives for effective antibiotics hosted by the Swedish EU presidency

  4. Methicillin-resistant S. aureus (MRSA) - most common multidrug resistant bacterium in EU MRSA in Europe 2006. S.aureus: Proportion of invasive isolates resistant to oxacillin (MRSA) in 2006. * These countries did not report any data or reported less than 10 isolates, Source: http://www.earss.rivm.nl, March 2008

  5. An increasing problem is resistance among Gram-negative bacteria The biggest challenge is treatment of infections caused by penicillin resistant bacteria so called ESBL (extended spectrum beta-lactamase) In Sweden, this year, 3 children died during a few weeks in neonatal care in a Swedish hospital due to a ESBL infection

  6. The industry has failed to launch new antibiotics • Between 1996 and 2004: more than 125 antibacterial screens on 60 different antibacterial targets were run by 34 companies • None of these efforts resulted in novel mechanism compounds. • Pharmaceutical companies left the antibacterial sector The industrial failure to meet the need of new antibacterial drugs indicates that novel approaches are needed to combat antibiotic resistant infections

  7. What can be done immediately? Create a task force on EU level and national level against antibiotic resistance to take immediate actions Legislation Restricted use of antibiotics, e. g. clear rules how antibiotics should be used in whole EU to minimize the spread of antibiotic resistance Surveillance/Epidemiology Develop a monitoring systems including a large database to monitor the epidemiology of antibiotic resistance and make this information rapidly available which also should include details about the infecting organism as such,meta-genomics

  8.  reduce the need of antibiotics through disease prevention What can be done immediately? Improve hygiene Combination therapy of known antibiotics to improve effect of treatment and possible resistance development New and improved methods for rapid diagnosis of the infectious agents and resistance patterns based on large scale genome sequencing

  9.  find new anti-bacterial agents or therapies with novel mechanisms of action that will limit resistance development What can be donein a sustainable perspective? Characteristics of the ideal novel antibiotic • Narrow spectrum • Coupled to rapid diagnosis • Not leading to resistance

  10. EU: international leading research on molecular mechanisms of microbial pathogenesis Areas of research that will have the highest probability to solve the antibiotic resistance problem: • Anti virulence strategies to disarm infectious bacteria • Functional genomics - targeted drug design • Continue high throughput screening of natural products • Novel vaccines based on meta-genomics • Therapeutic antibodies • Antibacterial peptides

  11. When do we expect results?

  12. Joint Programming- the way forward Maximise the effectiveness of research efforts through coordination of funding and resources Boost research advances and innovations Increase competitiveness of the EU on a global scale

  13. European Centre for Disease Control (ECDC) European Medicines Agency (EMEA) report: • > 25 000 patients in the EU die each year from infections caused by multidrug-resistant bacteria • antibacterial drug resistance - one of the major health threats in Europe

  14. EU: translational research Development of new antimicrobials in biotech companies: • Support for small and medium sized biotech companies needed • Coordinated funding in EU networks of excellence

  15. Epidemiology and surveillance Informatics based on genomics Rapid diagnosis Prevention and treatment of infection Rapid diagnosis Improved hygien Novel anti-microbial drugs

  16. Swedish MRSA cases 2000-2009

  17. Swedish ESBL cases 2005-2009

More Related